ARQIS has advised Liberta Partners on the sale of novelex AG to H&T Presspart, a division of Heitkamp & Thumann Group.
The company, headquartered in Nidau, Switzerland, is a specialist in the design, development and manufacture of complex total plastic solutions for the pharmaceutical, diagnostics and medical technology industries.
Liberta Partners is a multi-family holding company founded by entrepreneurs and based in Munich. Liberta Partners invests in companies predominantly based in German-speaking countries with operational and strategic development potential, in particular in company carve-outs and successions.
Since the acquisition of novelex by Liberta Partners, the revenue potential has increased significantly due to new product developments and the focus on research and development. In parallel, Liberta Partners completed the carve-out from the previous owner and strengthened the company together with its corporate development team.
H&T Presspart is a global leader in custom deep drawn and injection moulded parts for the pharmaceutical industry. The company specialises in the manufacture of pharmaceutical components and devices for drug delivery systems in the respiratory drug sector. H&T Presspart has three European production sites and sales offices in China, India, the USA and Uruguay. With the acquisition of novelex, H&T Presspart expands its focus for pharmaceutical customers and fully integrated product solutions.
ARQIS regularly advises Liberta Partners on transactions, as well as on fund structuring. For example, Dr Mauritz von Einem’s team advised on the acquisition of the tour operator Ameropa, a former subsidiary of Deutsche Bahn AG, as well as the acquisition of Kienzle Automotive.
